


ONLINE SUPPLEMENTARY DATA

Supplementary Figure 1. Challenges for patients with psoriatic arthritis. Rheumatologists (n=50) responded to the question: In the patient with oligoarticular psoriatic arthritis, what are the biggest challenges?



Supplementary Table 1. Characteristics of the surveyed rheumatologists.

Characteristics	All Respondents ^{a,b} N = 55
Location of practice, n (%)	
Alberta	4 (7.3)
British Columbia	6 (10.9)
Nova Scotia	1 (1.8)
Ontario	31 (53.4)
Quebec	12 (21.8)
Yukon	1 (1.8)
Years in practice, n (%)	
1–5	6 (10.9)
6–10	10 (18.2)
10–20	13 (23.6)
>20	26 (47.3)
Practice setting, n (%)	
Hospital based	13 (23.6)
Community based	26 (47.3)
Mixed	16 (29.1)
Number of ongoing clinical trials, n (%)	
0	32 (58.2)
1–3	21 (38.2)
3–10	2 (3.6)
10–30	0 (0.0)
>30	0 (0.0)

^aRheumatologists (55 of 64) responded to the following questions: What province do you practice in? How many years have you been in practice? Is your practice primarily: Hospital Based; Community Based; Mixed? Please identify the number of concurrent clinical trials that you are running.

^bThe version of the survey that used the term *moderate PsA* was completed by 31 respondents before September 16, 2018; after this date, 33 participants completed the second version of the survey that used the term *oligoarticular PsA*. Fifty-five participants responded to the questions presented here.

Supplementary Table 2. Percentage of Patients Receiving Treatment With Each Therapy Class for PsA^a.

Moderate PsA	Percentage of Patients With PsA Per Therapy Class										
	0-5%	6-10%	11-20%	21-30%	31-40%	41-50%	51-60%	61-70%	71-80%	81-90%	91-100%
Oral traditional DMARDs ^b	0	2	1	11	7	10	6	5	3	3	3
Injectable MTX	3	9	13	10	5	2	5	3	1	0	0
Oral targeted DMARD ^c	16	19	8	6	0	0	0	1	0	1	0
Biologic medication	4	6	16	11	5	6	1	1	1	0	0

^aRheumatologists (n = 51) responded to the question: Please estimate the percentage of your patients who are on the following therapy classes.

^bOral traditional DMARDs: methotrexate, leflunomide, antimalarials, sulfasalazine.

^cOral targeted DMARD: apremilast.

DMARD: disease-modifying anti-rheumatic drug; MTX: methotrexate; PsA: psoriatic arthritis.

Survey Questions^a

Demographics

1. How many years have you been in practice?
 - a. 1-5 years
 - b. 6-10 years
 - c. 10-20 years
 - d. > 20 years

2. What province do you practice in?
 - a. Alberta
 - b. British Columbia
 - c. Manitoba
 - d. New Brunswick
 - e. Nova Scotia
 - f. Ontario
 - g. Nunavut
 - h. Newfoundland and Labrador
 - i. Prince Edward Island
 - j. Quebec
 - k. Saskatchewan
 - l. Yukon

3. Please identify the number of concurrent clinical trials that you are running.
 - a. 0
 - b. 1-3
 - c. 3-10
 - d. 10-30
 - e. 30+

4. Is your practice primarily:
 - a. Hospital based
 - b. Community based
 - c. Mixed

Treatment Gap and Definition of Disease Severity

5. When considering all aspects of the disease that are important for you and your patient, how would you describe a patient who has **MODERATE/OLIGOARTICULAR** Psoriatic Arthritis?

(Check all that you utilize and specify the range/location)^b

- a. Patient Perception
 - b. HAQ specify range (from _ to _)
 - c. Work Productivity
 - d. Swollen joint count specify range (from _ to _)
 - e. Tender joint count specify range (from _ to _)
 - f. Severity of psoriasis
 - g. Presence of Enthesitis
 - h. Presence of Dactylitis
 - i. Location of inflammation specify
6. When considering all aspects of the disease that are important for you and your patient, how would you describe a patient who has **SEVERE** Psoriatic Arthritis?

(Check all that you utilize and specify the range)^b

- a. Patient Perception
 - b. HAQ specify range (above _)
 - c. Work Productivity
 - d. Swollen joint count specify range (above_)
 - e. Tender joint count specify range (above_)
 - f. Severity of psoriasis
 - g. Presence of Enthesitis
 - h. Presence of Dactylitis
 - i. Location of inflammation specify
7. In the patient with **MODERATE/OLIGOARTICULAR** psoriatic arthritis, what are the biggest challenges?

(check all that apply)

- a. Diagnosis
- b. when to initiate treatment
- c. patient acceptance
- d. treatment choices
- e. lack of treatments
- f. Presence of co-morbidity specify

- g. access to treatment
- h. other please specify

Perspective of Practice Composition

8. In the following Table, please estimate the percentage of your patients who are on the following therapy classes within each level of disease severity.
(Columns may add up to greater than 100%, because of combination therapy)

Disease state	Oral <u>traditional</u> DMARDs ^c	Injectable MTX	Oral <u>targeted</u> DMARD ^d	Biologic medications
Moderate	%	%	%	%
Severe	%	%	%	%

^aSegmentation questions used to determine eligibility for this analysis are excluded from this list.

^bRange and location were asked as follow-up questions if relevant.

^cOral traditional DMARDs: methotrexate, leflunomide, antimalarials, sulfasalazine.

^dOral targeted DMARD: apremilast. DMARDs: disease-modifying anti-rheumatic drugs; MTX: Methotrexate.